BREAKING: An expert consensus on early SCD risk in HFrEF patients has published in the Journal of Cardiac Failure (@JCardFail). The authors assessed contemporary evidence on SCD incidence in the modern era of GDMT including a review of the SCD-PROTECT (2025) study of nearly 20,000 consecutive LifeVest® WCD patients. One important finding: there’s a clear distinction between early and chronic SCD risk. Read the publication: onlinejcf.com/article/S1071-…

Reducing heart failure readmissions with earlier patient intervention. ZOLL Heart Failure Management System (HFMS) enables care teams to detect pulmonary fluid accumulation before symptoms develop, which helps clinicians act sooner and keep patients out of the hospital. For Carolyn, that meant: ✔️ Zero hospital visits for heart failure ✔️ Greater peace of mind ✔️ A return to everyday life Hear directly from Carolyn about her experience and from her prescriber, Chelsea Christensen, PA-C, on how HFMS is changing outcomes in her practice. ▶️ Watch the video below. Learn more about this real-world evidence: cardiac.zoll.com/medical-pro…

When early SCD risk is high, LifeVest delivers 23.4+ hours/day median compliance,¹⁻³ proven safety,¹ and proven efficacy.⁴⁻⁶ At #HFSA2026, ZOLL will highlight the latest SCD research, including SCD-PROTECT. Despite high utilization of 4-pillar GDMT, there were high LifeVest treatment rates across 19,500+ consecutive patients (NICM and MI/CAD), confirming the importance of early protection.1 Visit us in Booth 321 or review the latest research: cardiac.zoll.com/medical-pro… 1 David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, doi.org/10.1093/eurheartj/eh…; 2 Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268; 3 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis. 4 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation. 2015;132(17):1613–1619. 5 Data on file, 90d0241_a01. Report of AArD Performance during 2019. 6 Chung MK, Szykiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, & Tchou PJ (2010). Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. Journal of the American College of Cardiology, 56(3), 194–203.

Attending the HFSA Annual Scientific Meeting in Phoenix this weekend? Make plans to join ZOLL's Industry Expert Theater session: "Why is it time to rethink early SCD risk in HF?" Connect with experts Adam DeVore, MD, MHS and Ben D'Souza, MD, FACC, FHRS, for a discussion on early sudden cardiac death risk in heart failure and what it may mean for patient care. 📅 Saturday, October 10 ⏰ 8 a.m. - 8:45 a.m. MST 📍 Exhibit Hall, Theater 1 Add it to your schedule today. #HFSA2026 #HeartFailureScience #Cardiology

Heart failure management continues to evolve, and we're excited to be part of the conversation at the upcoming HFSA Annual Scientific Meeting. Don't miss Dr. Ahmad Barbour's poster presentation on new research evaluating the impact of inpatient initiation of ZOLL HFMS on heart failure readmissions. 📝 "Impact of Inpatient Initiation of Wearable Radiofrequency Thoracic Fluid Monitoring (ZOLL HFMS) on Heart Failure Readmissions: A Prospective Single-Center Study" 📅 Saturday, October 10 | 8:15 - 8:45 a.m. 📍 Oral Abstract Sessions, Monitor 1 Mark the session on your agenda, then visit Booth 321 at hashtag#HFSA2026 to learn more about ZOLL HFMS.

Coming to #HFSA2026? Meet the most comfortable LifeVest ever. Backed by results: ✅ 23.4+ hours/day compliance: Real-world and peer-reviewed data this decade¹⁻³ ✅ Incomparable Safety: The lowest inappropriate shock rate reported in contemporary WCD literature¹ ✅ Proven Efficacy: >97% first-shock success⁴⁻⁶ Visit us in Booth 321 or see our latest innovations: [link] 1 David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fu+D41dim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, doi.org/10.1093/eurheartj/eh…; 2 Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268; 3 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis. 4 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation. 2015;132(17):1613–1619. 5 Data on file, 90d0241_a01. Report of AArD Performance during 2019. 6 Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, & Tchou PJ (2010). Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. Journal of the American College of Cardiology, 56(3), 194–203.

📅 Save the Date for an Industry Expert Theater (IET) at HFSA 2026 Join ZOLL for an IET discussion exploring a critical question in heart failure care: Why is it time to rethink early SCD risk in HF? Hear insights from panelists Adam DeVore, MD, MHS and Ben D'Souza, MD as they discuss evolving perspectives on early sudden cardiac death risk in patients with heart failure. 🗓 Saturday, October 10 🕗 8 a.m. – 8:45 a.m. MST 📍 Exhibit Hall, Theater 1 We look forward to seeing you there! #HFSA2026 #HeartFailureScience #Cardiology

After a new heart failure diagnosis with reduced ejection fraction, Robbin was at risk for sudden cardiac arrest (SCA). When he experienced SCA, LifeVest® gave him a second chance. “I give thanks every day.” ▶️ Watch Robbin’s story and see how the right protection at the right time can save a life. #PatientStory #LifeVestSavesLives

"[ZOLL Heart Failure Management System] has been really game-changing and unique for us. The main reason that we feel that it has had a positive impact for us is the ability to get it on the patient right away when they depart and the manner in which we’re able to utilize the data that the device is giving us to make real-time adjustments to the patient’s GDMT [guideline-directed medical therapy] regimen and also coordinate with their whole outpatient cardiology team in an effort to really work hard to keep them out of the hospital.” - Dr. Isaac Humphrey, in a Cardio Care Today interview Read more: zollcms.com/45E6L1K

Heart failure does not have to mean frequent hospital readmissions. With ZOLL Heart Failure Management System, care teams can monitor pulmonary fluid levels remotely and intervene early if necessary. And patients like Carolyn can focus on getting back to their lives. ▶️ Watch the video to learn more.

What happens in the first 90 days after a heart failure diagnosis with reduced ejection fraction? For many patients, it’s a critical window: treatment has begun, but risk remains. Robbin McCombs’ story shows why sudden cardiac death protection matters during this time. Watch how LifeVest® helped him return to his daily life, knowing he was protected, and how it saved his life when he experienced sudden cardiac arrest. Watch 👇

In Cardio Care Today's latest video, Dr. Isaac Humphrey discusses how the temporary, patch-based ZOLL Heart Failure Management System (HFMS) is providing clinicians with actionable information during the critical post-discharge period. By helping teams intervene earlier, HFMS supports a more proactive approach to care and helps reduce readmissions. Read the full article: zollcms.com/45E6L1K

"LifeVest saved my life." Just weeks after being diagnosed with heart failure, Robbin experienced sudden cardiac arrest while sitting on his porch. The LifeVest® wearable defibrillator he was wearing detected it and delivered a lifesaving treatment. Stories like Robbin’s are a reminder: sudden cardiac arrest can happen anytime. Protection is critical, especially in the early days after diagnosis. ▶️Watch his story. #PatientStory #LifeVestSavesLives

Reducing heart failure readmissions with earlier patient intervention. ZOLL Heart Failure Management System (HFMS) enables care teams to detect pulmonary fluid accumulation before symptoms develop, which helps clinicians act sooner and keep patients out of the hospital. For Carolyn, that meant: ✔️ Zero hospital visits for heart failure ✔️ Greater peace of mind ✔️ A return to everyday life Hear directly from Carolyn about her experience and from her prescriber, Chelsea Christensen, PA-C, on how HFMS is changing outcomes in her practice. ▶️ Watch the video below. Learn more about this real-world evidence: zollcms.com/4i074Zi

The transition from hospital to home is a vulnerable period for patients with newly diagnosed heart failure. In a recent discussion with Cardio Care Today, Dr. Isaac Humphrey shares how remote pulmonary fluid monitoring with ZOLL Heart Failure Management System (HFMS) is helping care teams stay connected to patients after discharge, enabling earlier intervention, stronger patient engagement, and real-time adjustments to treatment plans. The goal: reduce avoidable readmissions while helping improve patient outcomes. Read more: zollcms.com/45E6L1K

Technology doesn't care about your ZIP code. But access to cardiovascular care often does. What happens when a patient experiencing a heart attack, cardiogenic shock, or advanced heart failure is hours from the nearest cardiologist or cath lab? On the newest episode of Cardiology Unscripted, Dr. @AndrewJSauer, advanced heart failure cardiologist and Vice President of Research at Saint Luke’s Health System, shares the realities of practicing cardiology in rural America. From limited resources and workforce shortages to delayed transfers and medication access challenges, the discussion highlights both the obstacles and opportunities in delivering high-quality cardiovascular care outside major metropolitan areas. You'll also hear how telemedicine, remote monitoring, APPs, and outreach programs are helping bring expert care to patients where they live. 🎧 Listen now: zollcms.com/4cralA4 #CardiologyUnscripted #CardiologyPodcast

Don't miss the opportunity to hear directly from VEST co-principal investigator Dr. Byron Lee (EP, Stanford University Medical Center), who will share his firsthand knowledge and expert perspective on the VEST research. Join us tonight for Insights from VEST and SCD-PROTECT. 📆 Wednesday, August 12 🕢 7:30 p.m. EDT 📍 Webinar Gain valuable insights into the research, its findings, and its implications from one of the study's leaders. Register here: zollcms.com/45q8sjg

Don't miss the opportunity to hear directly from VEST co-principal investigator Dr. Byron Lee (EP, Stanford University Medical Center), who will share his firsthand knowledge and expert perspective on the VEST research. Join us tonight for Insights from VEST and SCD-PROTECT. 📆 Wednesday, August 12 🕢 7:30 p.m. EDT 📍 Webinar Gain valuable insights into the research, its findings, and its implications from one of the study's leaders. Register here: zollcms.com/45q8sjg

With no symptoms and no prior cardiac issues, Robbin McCombs’s life changed quickly and unexpectedly when he was diagnosed with heart failure and a reduced ejection fraction (HFrEF). Two weeks after being prescribed LifeVest®, Robbin experienced sudden cardiac arrest while sitting on his porch. The device detected the dangerous arrhythmia and delivered a lifesaving treatment. Today, Robbin is here to share his story. Watch: #PatientStory #LifeVestSavesLives